12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Achillion preclinical data

In vitro, ACH-3102 provided higher potency than daclatasvir from Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) against HCV genotype 1a infection and comparable potency against HCV genotype 1b infection. Additionally, the combination of ...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >